Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Articles online first > Minerva Urology and Nephrology 2021 Mar 26



Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Urology and Nephrology 2021 Mar 26

DOI: 10.23736/S2724-6051.21.04098-4


lingua: Inglese

The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology

Matteo FERRO 1, Giuseppe LUCARELLI 2, Ottavio de COBELLI 1, Francesco DEL GIUDICE 3, Gennaro MUSI 1, Francesco A. MISTRETTA 1, Stefano LUZZAGO 1, Gian Maria BUSETTO 3, Carlo BUONERBA 4, Alessandro SCIARRA 3, Simon CONTI 5, Angelo PORRECA 7, Michele BATTAGLIA 2, Pasquale DITONNO 2, Matteo MANFREDI 8, Cristian FIORI 8, Francesco PORPIGLIA 8, Daniela TERRACCIANO 9

1 Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy; 2 Department of Emergency & Organ Transplantation - Urology, Andrology & Kidney Transplantation Unit, University of Bari, Bari, Italy; 3 Department of Urology, Sapienza University of Rome, Roma, Italy; 4 Medical Oncology, Department of Clinical Medicine & Surgery, University Federico II, Naples, Italy; 5 Department of Urology, Stanford University, School of Medicine, Stanford, UK; 6 Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, Milan, Italy; 7 Department of Urology, Abano Terme Hospital, Padua, Italy; 8 Division of Urology, Department of Oncology, School of Medicine, San Luigi Hopsital, University of Turin, Orbassano, Turin, Italy; 9 Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy


Molecular heterogeneity and availability of different therapeutic strategies are relevant clinical features of prostate cancer. On this basis, there is an urgent need to identify prognostic and predictive biomarkers for an individualized therapeutic approach. In this context, researchers focused their attention on biomarkers able to discriminate potential life-threatening from organ-confined disease identify high-grade tumors. Such biomarker could provide aid in clinical decision making, helping in order to choose the treatment which ensures the best results in terms of patient survival and quality of life. To address this need, many new laboratory tests have been proposed, witha clear tendency to use panels of combined biomarkers. In this review we evaluate current data on the application in clinical practice for of the most promising laboratory tests: Phi, 4Kscore and Stockholm 3 as circulating biomarkers, and Mi-prostate score, Exo DX Prostate and Select MD-X as urinary biomarkers, Confirm MDx, Oncotype Dx, Prolaris and Decipher as tissue biomarkers. In particular, the ability of these tests in the identification of clinically significant PCa and their potential use for precision medicine have been explored in this review.

KEY WORDS: Phi; Stockholm 3; 4K score; Select MDx; ExoDX prostate; Mi-Prostate score

inizio pagina